Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)

Wenyin Shi; Erik S. Blomain; Joshua Siglin; Joshua D. Palmer; Tu Dan; Yang Wang; Maria Werner-Wasik; Jon Glass; Lyndon Kim; Voichita Bar Ad; Deepak Bhamidipati; James J. Evans; Kevin Judy; Christopher J. Farrell; David W. Andrews

doi:10.1007/s11060-018-2744-5

Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)

Wenyin Shi, Erik S. Blomain, Joshua Siglin, Joshua D. Palmer, Tu Dan, Yang Wang, Maria Werner-Wasik, Jon Glass, Lyndon Kim, Voichita Bar Ad, Deepak Bhamidipati, James J. Evans, Kevin Judy, Christopher J. Farrell, David W. Andrews

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The fourth author’s name was incorrect in the initial online publication. The original article has been corrected.

Original language	English (US)
Pages (from-to)	179
Number of pages	1
Journal	Journal of Neuro-Oncology
Volume	137
Issue number	1
DOIs	https://doi.org/10.1007/s11060-018-2744-5
State	Published - Mar 1 2018

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-018-2744-5

Fingerprint

Dive into the research topics of 'Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)'. Together they form a unique fingerprint.

Cite this

Shi, W., Blomain, E. S., Siglin, J., Palmer, J. D., Dan, T., Wang, Y., Werner-Wasik, M., Glass, J., Kim, L., Bar Ad, V., Bhamidipati, D., Evans, J. J., Judy, K., Farrell, C. J., & Andrews, D. W. (2018). Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0). Journal of Neuro-Oncology, 137(1), 179. https://doi.org/10.1007/s11060-018-2744-5

Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0). / Shi, Wenyin; Blomain, Erik S.; Siglin, Joshua et al.
In: Journal of Neuro-Oncology, Vol. 137, No. 1, 01.03.2018, p. 179.

Research output: Contribution to journal › Comment/debate › peer-review

Shi, W, Blomain, ES, Siglin, J, Palmer, JD, Dan, T, Wang, Y, Werner-Wasik, M, Glass, J, Kim, L, Bar Ad, V, Bhamidipati, D, Evans, JJ, Judy, K, Farrell, CJ & Andrews, DW 2018, 'Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)', Journal of Neuro-Oncology, vol. 137, no. 1, pp. 179. https://doi.org/10.1007/s11060-018-2744-5

Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y et al. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0). Journal of Neuro-Oncology. 2018 Mar 1;137(1):179. doi: 10.1007/s11060-018-2744-5

@article{15de31e2e0fc4d05a54293bc3b7064c0,

title = "Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)",

abstract = "The fourth author{\textquoteright}s name was incorrect in the initial online publication. The original article has been corrected.",

author = "Wenyin Shi and Blomain, {Erik S.} and Joshua Siglin and Palmer, {Joshua D.} and Tu Dan and Yang Wang and Maria Werner-Wasik and Jon Glass and Lyndon Kim and {Bar Ad}, Voichita and Deepak Bhamidipati and Evans, {James J.} and Kevin Judy and Farrell, {Christopher J.} and Andrews, {David W.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = mar,

day = "1",

doi = "10.1007/s11060-018-2744-5",

language = "English (US)",

volume = "137",

pages = "179",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)

AU - Shi, Wenyin

AU - Blomain, Erik S.

AU - Siglin, Joshua

AU - Palmer, Joshua D.

AU - Dan, Tu

AU - Wang, Yang

AU - Werner-Wasik, Maria

AU - Glass, Jon

AU - Kim, Lyndon

AU - Bar Ad, Voichita

AU - Bhamidipati, Deepak

AU - Evans, James J.

AU - Judy, Kevin

AU - Farrell, Christopher J.

AU - Andrews, David W.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The fourth author’s name was incorrect in the initial online publication. The original article has been corrected.

AB - The fourth author’s name was incorrect in the initial online publication. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85042382547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042382547&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-2744-5

DO - 10.1007/s11060-018-2744-5

M3 - Comment/debate

C2 - 29313182

AN - SCOPUS:85042382547

SN - 0167-594X

VL - 137

SP - 179

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 1

ER -

Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this